Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — Alk-Abello As B Shs New — Q1 2024 Earnings Presentation
12 slides from Alk-abello A/s Class B's earnings presentation, May 3, 2024
Slide 1: Q1 2024 presentation
Q1 2024 presentation Webcast 3 May 2024
Slide 2: Agenda and presenters
2 Webcast 3 May 2024 Agenda and presenters • Q1 highlights • Performance o European tablet sales o Global sales and market trends o Financials • Strategy President & CEO EVP, Group CFO VP, Head of IR o Status on current priorities Peter Halling Claus Steensen Sølje Per Plotnikof o Update on ongoing
Slide 3: Q1: Robust start to the year
3 Webcast 3 May 2024 Q1: Robust start to the year Full-year guidance updated • 10% growth in total revenue, EBIT up 41% • 22% growth in global tablet sales, 28% growth in Europe • USA and China impacted by fluctuations and phasing • Strategic initiatives to optimise ALK’s business platform Revenue +
Slide 4: Update on European tablet sales
4 Webcast 3 May 2024 Update on European tablet sales Q1 sales exceeded expectations • Strong inflow of new patients vs. weak quarter last year • Focused sales & marketing activities since spring ‘23 • Accelerating market transition in Germany • Improved pricing, including rebate adjustments ITULAZAX
Slide 5: Strong growth in Europe
5 Webcast 3 May 2024 Strong growth in Europe Tablets key to growth in Europe Europe North America International markets Share of Q1 revenue Share of Q1 revenue Share of Q1 revenue 11% 16% 73% 226m 992m 211m 148m 1,558m +18% +2% -18% 837m 209m 188m 1,504m Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 20
Slide 6: High double-digit growth in tablet sales
6 Webcast 3 May 2024 High double-digit growth in tablet sales Double-digit growth in tablet sales in Europe and North America Tablets SCIT/SLIT-drops Other products Share of revenue Share of revenue Share of revenue 11% 52% 37% 706m 500m 145m +22% 483m -1% +1% 581m 510m 143m Q1 2024 Q1 2023 Q1 2024
Slide 7: Sales growth drives margin improvements
7 Webcast 3 May 2024 Sales growth drives margin improvements Best ever quarterly performance DKK million Q1 2023 Q1 2024 Change Gross profit DKKm Gross profit Margin % % Revenue 1,234 1,351 +10% 1,000 70 800 68 Gross profit 799 889 600 66 400 64 Gross margin 65% 66% 200 62 0 60 Capacity costs 571 57
Slide 8: Strategic priorities 2024
8 Webcast 3 May 2024 Strategic priorities 2024 Follow-up on 2024 agenda • Maintain regained momentum in tablets - especially in Europe • Secure regulatory approvals for children use o ACARIZAX® / ODACTRA® approval expected in late 2024 and 2025 for Europa and North America, respectively o ITULAZAX®/
Slide 9: Update on ongoing strategy review
9 Webcast 3 May 2024 Update on ongoing strategy review Unchanged ambition of an EBIT margin of ~25% in 2025 • Sustain high revenue growth • Prioritisation of high growth areas • Optimisation initiatives o Organisational adjustments (incl. FTE reductions) o Streamlining of processes and procurement s
Slide 10: Full-year outlook updated
10 Webcast 3 May 2024 Full-year outlook updated 2024 Revenue Assumptions 10-13% Revenue • Double-digit growth in tablet sales – EU sales growth DKKm Growth in l.c. % 6,000 16 to rebound to a level significantly above 2023 4,500 12 Growth in • Continued growth for SCIT/SLIT, although at a 3,000 8 loc
Slide 11: Q&A session
Q&A session
Slide 12: Upcoming news and events
12 Webcast 3 May 2024 Upcoming news and events 6 May Roadshow, Copenhagen 4 June Capital Markets Day, Hørsholm, DK 23 August Six-month interim report (Q2) 2024 Investor Relations: Per Plotnikof, Vice President, Head of Investor Relations Phone: +45 4574 7576 E-mail: ppidk@alk.net www.alk.net
Alk-Abello As B Shs New — Q1 2024 Earnings Presentation on 6ix